An array of possibilities in cancer research using cytokine antibody arrays

Expert Review of Proteomics

Volumn 4, Issue 2, 2007, Pages 299-308

  Huang, Ruo Pan ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody array; Biomarker; Cancer; Cytokine; Drug discovery; Expression profile; Proteomics

Indexed keywords

ALPHA TOCOPHEROL; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYTOKINE; CYTOKINE ANTIBODY; INTEGRIN; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; NEUTRALIZING ANTIBODY; PROBIOTIC AGENT; RECOMBINANT PROTEIN; THALIDOMIDE; TOCOPHEROL;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RESEARCH; CARCINOGENESIS; CLINICAL TRIAL; CLOSTRIDIUM; COLON CANCER; DENDRITIC CELL; DNA MICROARRAY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; HUMAN; KIDNEY CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MICROARRAY; PROTEOMICS; RADIATION PROTECTION; REVIEW; SUBCUTANEOUS TISSUE TUMOR; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

ANTIBODIES; CYTOKINES; HUMANS; IMMUNOASSAY; METHODS; NEOPLASMS; PROTEIN ARRAY ANALYSIS; RESEARCH;

EID: 34247167980     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.4.2.299     Document Type: Review

References (104)

1. Kulbe H, Levinson NR, Balkwill F et al. The chemokine network in cancer - much more than directing cell movement. Int. J. Dev. Biol. 48(5-6), 489-496 (2004).
2. Huang R, Lin Y, Shi Q et al. Profiling of angiogenesis factors in gynecological malignancies by enhanced protein profiling arrays. Clin. Cancer Res. 10, 598-609 (2004).
3. Rao VS, Dyer CE, Jameel JK et al. Potential prognostic and therapeutic roles for cytokines in breast cancer (review). Oncol. Rep. 15(1), 179-185 (2006).
4. Bauskin AR, Brown DA, Kuffner T et al. Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res. 66(10), 4983-4986 (2006).
5. Langowski JL, Zhang X, Wu L et al. IL-23 promotes tumour incidence and growth. Nature 442, 441-445 (2006).
6. Culig Z, Steiner H, Bartsch G et al. Interleukin-6 regulation of prostate cancer cell growth. J. Cell. Biochem. 93(3), 497-505 (2005).
7. Bellone S, Watts K, Cane' S et al. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol. Oncol. 98(1), 92-98 (2005).
8. Kobayashi S, Werneburg NW, Bronk SF et al. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 128(7), 2054-2065 (2005).
9. Ravatn R, Wells V, Nelson L et al. Circumventing multidrug resistance in cancer by β-galactoside binding protein, an antiproliferative cytokine. Cancer Res. 65(5), 1631-1634 (2005).
10. Smyth MJ, Cretney E, Kershaw MH et al. Cytokines in cancer immunity and immunotherapy. Immunol. Rev. 202, 273-293 (2004).
11. Apte RN, Voronov E. Interleukin-1 - a major pleiotropic cytokine in tumor-host interactions. Semin. Cancer Biol. 12(4), 277-290 (2002).
12. Muller G, Hopken UE, Stein H et al. Systemic immunoregulatory and pathogenic functions of homeostatic chemokine receptors. J. Leukoc. Biol. 72(1), 1-8 (2002).
13. Hurle RA, Davies G, Parr C et al. Hepatocyte growth factor/scatter factor and prostate cancer: a review. Histol. Histopathol. 20(4), 1339-1349 (2005).
14. Vom DF, Wullich B, Gulbins E et al. Molecular biology approach to explain lymphatic metastasis. Urologe A 44(6), 608-613 (2005).
15. Salgado R, Junius S, Benoy I et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int. J. Cancer 103(5), 642-646 (2003).
16. Bower JE, Ganz PA, Aziz N et al. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom. Med. 64(4), 604-611 (2002).
17. Zhang G, Li W, Holle L et al. A novel design of targeted endocrine and cytokine therapy for breast cancer. Clin. Cancer Res. 8(4), 1196-1205 (2002).
18. Zaenker KS. Infection, inflammation and neoplasia: an interdisciplinary challenge. Contrib. Microbiol. 13, 232-239 (2006).
19. Mignogna MD, Fedele S, Lo RL et al. Immune activation and chronic inflammation as the cause of malignancy in oral lichen planus: is there any evidence? Oral Oncol. 40(2), 120-130 (2004).
20. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer 41(16), 2502-2512 (2005).
21. Il'yasova D, Colbert LH, Harris TB et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol. Biomarkers Prev. 14(10), 2413-2418 (2005).
22. Horiguchi A, Oya M, Marumo K et al. STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P. Kidney Int. 61(3), 926-938 (2002).
23. Huang SP, Wu MS, Wang HP et al. Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma. J. Gastroenterol. Hepatol. 17(11), 1165-1169 (2002).
24. Srivani R, Nagarajan B. A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer. Int. J. Gynecol. Cancer 13(3), 331-339 (2003).
25. Ishikawa H, Tsuyama N, Liu S et al. Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals. Oncogene 24(41), 6328-6332 (2005).
26. Lazar-Molnar E, Hegyesi H, Toth S et al. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12(6), 547-554 (2000).
27. Hammacher A, Thompson EW, Williams ED. Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgen-refractory and metastatic prostate cancer. Int. J. Biochem. Cell Biol. 37(2), 442-450 (2005).
28. Pedranzini L, Dechow T, Berishaj M et al. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res. (19), 9714-9721 (2006).
29. Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 65(23), 10794-10800 (2005).
30. Duan Z, Foster R, Bell DA et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin. Cancer Res. 12(17), 5055-5063 (2006).
31. Domingo-Domenech J, Oliva C, Rovira A et al. Interleukin 6, a nuclear factor-κB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-κB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin. Cancer Res. 12(18), 5578-5586 (2006).
32. Lee SO, Lou W, Johnson CS et al. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat 3 pathway. Prostate 60, 78-86 (2004).
33. Wallner L, Dai J, Escara-Wilke J et al. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res. 66(6), 3087-3095 (2006).
34. Bozcuk H, Uslu G, Samur M et al. Tumour necrosis factor-α, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine 27, 58-65 (2004).
35. Bozcuk H, Uslu G, Samur M et al. Predictors of distant metastasis at presentation in breast cancer: a study also evaluating associations among common biological indicators. Breast Cancer Res. Treat. 68(3), 239-248 (2001).
36. Trikha M, Corringham R, Klein B et al. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin. Cancer Res. 9, 4653-4665 (2003).
37. Maggio M, Guralnik JM, Longo DL et al. Interleukin-6 in aging and chronic disease: a magnificent pathway. J. Gerontol. A Biol. Sci. Med. Sci. 61(6), 575-584 (2006).
38. Scheller J, Ohnesorge N, Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand. J. Immunol. 63, 321-329 (2006).
39. Huang RP. Simultaneous detection of multiple proteins with an array-based enzyme-linked immunosorbent assay (ELISA) and enhanced chemiluminescence (ECL). Clin. Chem. Lab. Med. 39(3), 209-214 (2001).
40. Huang RP. Detection of multiple proteins in an antibody-based protein microarray system. J. Immunol. Methods 255(1-2), 1-13 (2001).
41. Huang RP, Huang R, Fan Y et al. Simultaneous detection of multiple cytokines from conditioned media and patient's sera by an antibody-based protein array system. Anal. Biochem. 294(1), 55-62 (2001). • First demonstration of the application of cytokine antibody arrays in patient specimen and tissue culture samples.
42. Lin Y, Huang R, Cao X et al. Detection of multiple cytokines by protein arrays from cell lysate and tissue lysate. Clin. Chem. Lab. Med. 41(2), 139-145 (2003). • First report of biotin-label-based cytokine antibody arrays.
43. Huang RP. Cytokine antibody arrays: a promising tool to identify molecular targets for drug discovery. Comb. Chem. High Throughput. Screen. 6(8), 769-775 (2003). •• Good review of the application of cytokine antibody arrays in drug discovery.
44. Huang RP. Cytokine protein arrays. Methods Mol. Biol. 278, 215-232 (2004).
45. Knight PR, Sreekumar A, Siddiqui J et al. Development of a sensitive microarray immunoassay and comparison with standard enzyme-linked immunoassay for cytokine analysis. Shock 21(1), 26-30 (2004).
46. Moody MD, Van Arsdell SW, Murphy KP et al. Array-based ELISAs for high-throughput analysis of human cytokines. Biotechniques 31(1), 186-4 (2001). • First description of a 96-well-plate format of antibody arrays.
47. Lin Y, Huang R, Chen LP et al. Profiling of cytokine expression by biotin-labeled-based protein arrays. Proteomics 3(9), 1750-1757 (2003).
48. Schweitzer B, Roberts S, Grimwade B et al. Multiplexed protein profiling on microarrays by rolling-circle amplification. Nat. Biotechnol. 20(4), 359-365 (2002). •• Excellent report demonstrating that rolling-circle amplification can greatly enhance detection sensitivity in cytokine antibody arrays.
49. Martoglio AM, Tom BD, Starkey M et al. Changes in tumorigenesis- and angiogenesis-related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA arrays. Mol. Med. 6(9), 750-765 (2000).
50. Ismail RS, RL Baldwin, J Fang et al. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res. 60(23), 6744-6749 (2000).
51. Welsh JB, Zarrinkar PP, Sapinoso LM et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl Acad. Sci. USA 98(3), 1176-1181 (2001).
52. Sawiris GP, Sherman-Baust CA, Becker KG et al. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. Cancer Res. 62(10), 2923-2928 (2002).
53. Kingsmore SF, Patel DD. Multiplexed protein profiling on antibody-based microarrays by rolling circle amplification. Curr. Opin. Biotechnol. 14(1), 74-81 (2003).
54. Yamasaki M, Kitagawa T, Chujo H et al. Physiological difference between free and triglyceride-type conjugated linoleic acid on the immune function of C57BL/6N mice. J. Agric. Food Chem. 52(11), 3644-3648 (2004).
55. Dave B, Eason RR, Geng Y et al. Tp53-associated growth arrest and DNA damage repair gene expression is attenuated in mammary epithelial cells of rats fed whey proteins. J. Nutr. 136, 1156-1160 (2006).
56. Brown JM, Boysen MS, Chung S et al. Conjugated linoleic acid induces human adipocyte delipidation: autocrine/paracrine regulation of MEK/ERK signaling by adipocytokines. J. Biol. Chem. 279(25), 26735-26747 (2004).
57. Sharma M, Arnason JT, Burt A et al. Echinacea extracts modulate the pattern of chemokine and cytokine secretion in rhinovirus-infected and uninfected epithelial cells. Phytother. Res. 20, 147-152 (2006).
58. Lin Y, Huang R, Santanam N et al. Profiling of human cytokines in healthy individuals with vitamin E supplementation by antibody array. Cancer Lett. 187(1-2), 17-24 (2002).
59. Huang R, Lin Y, Flowers L et al. Molecular profiling of cytokine levels in human ovarian cancer patients. Cancer Genomics Proteomics 1, 23-32 (2004).
60. Celis JE, Gromov P, Cabezon T et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol. Cell. Proteomics 3(4), 327-344 (2004). • Outstanding cancer proteomic research programs involving multiple approaches.
61. Pockaj BA, Basu GD, Pathangey LB et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann. Surg. Oncol. 11(3), 328-339 (2004).
62. Dvorakova K, Payne CM, Ramsey L et al. Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus. Clin. Cancer Res. 10(6), 2020-2028 (2004).
63. Hegmans JP, Hemmes A, Hammad H et al. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur. Respir. J. 27(6), 1086-1095 (2006).
64. Celis JE, Celis P, Ostergaard M et al. Proteomics and immunohistochemistry define some of the steps involved in the squamous differentiation of the bladder transitional epithelium: a novel strategy for identifying metaplastic lesions. Cancer Res. 59(12), 3003-3009 (1999).
65. Tadros Y, Ruiz-Deya G, Crawford BE et al. In vivo proteomic analysis of cytokine expression in laser capture-microdissected urothelial cells of obstructed ureteropelvic junction procured by laparoscopic dismembered pyeloplasty. J. Endourol. 17(5), 333-336 (2003).
66. De S, Razorenova O, McCabe NP et al. VEGF-integrin interplay controls tumor growth and vascularization. Proc. Natl Acad. Sci. USA 102(21), 7589-7594 (2005).
67. Wang S, Yang J, Qian J et al. Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 107, 2432-2439 (2006).
68. Kim BG, Li C, Qiao W et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 441(7096), 1015-1019 (2006). • Creative application of cytokine antibody arrays in routine research.
69. Oh HS, Moharita A, Potian JG et al. Bone marrow stroma influences transforming growth factor-β production in breast cancer cells to regulate c-myc activation of the preprotachykinin-I gene in breast cancer cells. Cancer Res. 64, 6327-6336 (2004).
70. Yun CC, Sun H, Wang D et al. LPA2 receptor mediates mitogenic signals in human colon cancer cells. Am. J. Physiol. Cell Physiol. 289(1), 2-11 (2005).
71. Deroanne CF, Hamelryckx D, Ho TT et al. Cdc42 downregulates MMP-1 expression by inhibiting the ERK1/2 pathway. J. Cell Sci. 118, 1173-1183 (2005).
72. Sordi V, Malosio ML, Marchesi F et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 106, 419-427 (2005).
73. Cohen CJ, Zheng Z, Bray R et al. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J. Immunol. 175, 5799-5808 (2005).
74. Meyer-Siegler KL, Leifheit EC, Vera PL. Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. BMC Cancer 4(34), 1-12 (2004).
75. Rethi B, Gogolak P, Szatmari I et al. SLAM/SLAM interactions inhibit CD40-induced production of inflammatory cytokines in monocyte-derived dendritic cells. Blood 107, 2821-2829 (2006).
76. Giroux M, Denis F. Human CD1d-unrestricted NKT cells release chemokines upon Fas engagement. Blood 105(2), 703-710 (2004).
77. Wang G, Tschoi M, Spolski R et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 63, 9016-9022 (2003).
78. Agrawal N, Bettegowda C, Cheong I et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc. Natl Acad. Sci. USA 101(42), 15172-15177 (2004).
79. Singh VK, Shafran RL, Jackson WE III et al. Induction of cytokines by radioprotective tocopherol analogs. Exp. Mol. Pathol. 81, 55-61 (2006).
80. DeCicco KL, Tanaka T, Andreola F et al. The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARγ pathway. Carcinogenesis 25(10), 1805-1812 (2004).
81. Huang R, Lin Y, Wang CC et al. Connexin 43 suppresses human glioblastoma cell growth by down-regulation of monocyte chemotactic protein 1, as discovered using protein array technology. Cancer Res. 62(10), 2806-2812 (2002).
82. Dehqanzada ZA, Storrer CE, Hueman MT et al. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Clin. Cancer Res. 15(2), 478-486 (2006).
83. Lu Y, Cai Z, Galson DL et al. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 66(12), 1311-1318 (2006).
84. Azenshtein E, Luboshits G, Shina S et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 62(4), 1093-1102 (2002).
85. Moran CJ, Arenberg DA, Huang CC et al. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin. Cancer Res. 8(12), 3803-3812 (2002).
86. Tsukishiro S, Suzumori N, Nishikawa H et al. Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder. Gynecol. Oncol. 102(3), 542-545 (2006).
87. Vaday GG, Peehl DM, Kadam PA et al. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 66(2), 124-134 (2006).
88. Hong KJ, Dunn DM, Shen CL et al. Effects of Ganoderma lucidum on apoptotic and anti-inflammatory function in HT-29 human colonic carcinoma cells. Phytother. Res. 18, 768-770 (2004).
89. Celis JE, Moreira JM, Cabezon T et al. Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol. Cell. Proteomics 4, 492-522 (2005).
90. Celis JE, Gromova I, Moreira JM et al. Impact of proteomics on bladder cancer research. Pharmacogenomics 5(4), 381-394 (2004).
91. Kuusniemi AM, Lapatto R, Holmberg C et al. Kidneys with heavy proteinuria show fibrosis, inflammation, and oxidative stress, but no tubular phenotypic change. Kidney Int. 68(1), 121-132 (2005).
92. Panelli MC, White R, Foster M et al. Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J. Transl. Med. 2, 1-14 (2004).
93. Nakamura Y, Nawata M, Wakitani S. Expression profiles and functional analyses of Wnt-related genes in human joint disorders. Am. J. Pathol. 167(1), 97-105 (2005).
94. Marks DJ, Harbord MW, MacAllister R et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 367 (9511), 668-678 (2006).
95. Vargas DL, Nascimbene C, Krishnan C et al. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann. Neurol. 57(1), 67-81 (2004).
96. Nichols MT, Gidey E, Matzakos T et al. Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid. Hepatology 40(4), 836-846 (2004).
97. Kaukola T, Satyaraj E, Patel DD et al. Cerebral palsy is characterized by protein mediators in cord serum. Ann. Neurol. 55(2), 186-194 (2004).
98. Xu Y, Kulkosky J, Acheampong E et al. HIV-1-mediated apoptosis of neuronal cells: proximal molecular mechanisms of HIV-1-induced encephalopathy. Proc. Natl Acad. Sci. USA 101(18), 7070-7075 (2004).
99. Krishnan C, Kaplin AI, Graber JS et al. Recurrent transverse myelitis following neurobrucellosis: immunologic features and beneficial response to immunosuppression. J. Neurovirol. 11(2), 225-231 (2005).
100. Rupprecht TA, Pfister HW, Angele B et al. The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis. Neurology 65(3), 448-450 (2005).
101. Kastenbauer S, Angele B, Sporer B et al. Patterns of protein expression in infectious meningitis: a cerebrospinal fluid protein array analysis. J. Neuroimmunol. 164(1-2), 134-139 (2005).
102. Klein M, Paul R, Angele B et al. Protein expression pattern in experimental pneumococcal meningitis. Microbes Infect. 8(4), 973-983 (2006).
103. Kaplin AI, Deshpande DM, Scott E et al. IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J. Clin. Invest. 115(10), 2731-2741 (2005).
104. Turtinen LW, Prall DN, Bremer LA et al. Antibody array-generated profiles of cytokine release from THP-1 leukemic monocytes exposed to different amphotericin B formulations. Antimicrob. Agents Chemother. 48(2), 396-403 (2004).